XTL Biopharmaceuticals Ltd. is dedicated to the acquisition and development of late-stage pharmaceutical products aimed at addressing unmet clinical needs. The company focuses on systematically identifying and validating therapeutic candidates that offer advantages over existing treatments. Currently, XTL is advancing three compounds through various clinical stages, including hCDR1 for the treatment of Systematic Lupus Erythematosus and Recombinant Human Erythropoietin (rHuEPO) for Multiple Myeloma. This strategic approach allows XTL to target significant medical gaps and enhance patient outcomes.

The XTLbio pipeline emphasizes the importance of in-licensing promising therapeutic candidates that can potentially improve upon current therapies. By concentrating on late-stage product candidates, XTL aims to expedite the development process and bring innovative treatments to market more efficiently. The company’s commitment to addressing unmet medical needs is reflected in its active clinical development of these compounds, which are designed to provide effective solutions for patients suffering from serious health conditions.

Israel

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.

The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

XTL Biopharmaceuticals Ltd.

Company Details